Mostrar mensagens com a etiqueta Clinical Trial. Mostrar todas as mensagens
Mostrar mensagens com a etiqueta Clinical Trial. Mostrar todas as mensagens

domingo, 11 de junho de 2017

Base de dados de ensaios clínicos (estudos)

Os estudos são a maior fonte de notícias na comunicação social sobre nutrição, saúde e afins. Exemplo de uma base de dados com estudos (Estados Unidos, e não só):
https://clinicaltrials.gov/

Citando:
"ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Learn more about clinical studies and about this site, including relevant history, policies, and laws."


segunda-feira, 6 de fevereiro de 2017

Tratamento experimental para cancro dos pulmões

Tratamento experimental recupera doente de cancro dos pulmões:

Terminally ill lung cancer patient given all clear after world first drug trial - Mirror Online

Quoting:
"Bob wasn’t responding to the drugs, and doctors told him he had around a year-and-a-half left to live. They decided to transfer him to the hospital’s clinical trials unit, and 12 months ago Bob became one of the first people ever to be treated with the brand new drug, which can’t yet be named."



segunda-feira, 26 de dezembro de 2016

Vacina para o Ébola?

Para os críticos da medicina ocidental, são notícias como estas que - a serem confirmad os fazem pensar duas vezes (relembrando que o vírus do Ébola é algo que provoca uma morte terrível em dias, mas que o faz "lá longe", em África):
http://www.independent.co.uk/news/world/africa/ebola-vaccine-protection-against-virus-guinea-who-trials-a7492931.html



quarta-feira, 21 de dezembro de 2016

Terapia não invasiva de cancro da próstata (laser)...

... E a importância da biodiversidade (bactérias marinhas foram a inspiração):


http://m.scmp.com/tech/innovation/article/2056369/new-form-therapy-involving-lasers-could-transform-way-prostate


Citando:
"A clinical trial has shown that a new, non-surgical method of treatment for low-risk prostate cancer can effectively kill cancer cells whilst at the same time preserving healthy tissue.
The new treatment is called vascular-targeted photodynamic therapy, or VTP. According to University College London Hospitals (UCLH), the treatment uses a light-sensitive drug, which is injected into the bloodstream. A laser then activates the drug, which eradicates tumour tissue in the prostate.



The drug used is called WST11 and comes from bacteria found at the bottom of the ocean. These bacteria have evolved to turn light into energy in a very efficient way. This trait has been exploited to develop WST11, which UCLH describes as “a compound that releases free radicals to kill surrounding cells when activated by laser light.”"

domingo, 5 de junho de 2016

Exemplo de Press Release de Ensaios Clínicos

Um exemplo de PR com que me cruzei por estes dias com referência às diversas fases dos ensaios, os efeitos secundários detectados e os eventos de determinada gravidade (SAEs Grade 1-5).
Interessante (mas não surpreendente) o sítio aonde é publicado: Uk.finance.yahoo.com.


Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016:
https://uk.finance.yahoo.com/news/ignyta-announces-interim-data-phase-130000822.html

segunda-feira, 7 de dezembro de 2015

O negócio do cancro

Sobre o negócio do cancro e porque é que os SNSs deviam apostar muito mais na prevenção do que no tratamento, as respostas estão por todo o lado:


http://www.stardailystandard.com/breaking/novartis-lymphoma-research-exhibits-cart-on-monitor-for-2017-us-submission/43165/
Nomeadamente no meio milhão de dólares por doente (custo estimado pelos peritos):


Citando:
"With CTL019, also being studied by Novartis on children with advanced leukemia, the Basel-based drug giant has joined smaller rivals including Juno Therapeutics and Kite Pharma seeking to launch new, more-effective – and likely very expensive – treatments for blood cancers.
Analysts expect CART therapies to command prices up to US$450,000 when they hit the market by 2017. Novartis acknowledged costs will be high, but declined to give dimensions
(...)"